标题
Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
作者
关键词
-
出版物
Frontiers in Immunology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-05-22
DOI
10.3389/fimmu.2019.00999
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
- (2018) Robert L. Ferris et al. CANCER TREATMENT REVIEWS
- Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
- (2018) Silvia C. Formenti et al. CLINICAL CANCER RESEARCH
- Bifacial effects of engineering tumour cell-derived exosomes on human natural killer cells
- (2018) Qi Li et al. EXPERIMENTAL CELL RESEARCH
- The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer
- (2018) Xiaoling Xu et al. INTERNATIONAL JOURNAL OF CANCER
- Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
- (2018) Junko Tanizaki et al. Journal of Thoracic Oncology
- Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma
- (2018) Kendra C. Foley et al. MELANOMA RESEARCH
- mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma
- (2018) Yuhua Wang et al. MOLECULAR THERAPY
- Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT
- (2018) Elizabeth K. Duperret et al. MOLECULAR THERAPY
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
- (2018) Natalie J. Neubert et al. Science Translational Medicine
- The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer
- (2018) Rindert Missiaen et al. SEMINARS IN CANCER BIOLOGY
- The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
- (2018) Yayi He et al. Drug Design Development and Therapy
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
- (2018) David A. Schaer et al. Cell Reports
- Immuno-Oncology: Emerging Targets and Combination Therapies
- (2018) Henry T. Marshall et al. Frontiers in Oncology
- Cemiplimab Approved for Treatment of CSCC
- (2018) Cancer Discovery
- Second- and third-generation drugs for immuno-oncology treatment—The more the better?
- (2017) Wolfram C.M. Dempke et al. EUROPEAN JOURNAL OF CANCER
- Immune recognition of irradiated cancer cells
- (2017) Erik Wennerberg et al. IMMUNOLOGICAL REVIEWS
- Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality
- (2017) Andreas Pircher et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Current status and future prospects of the strategy of combining CAR‑T with PD‑1 blockade for antitumor therapy (Review)
- (2017) Jinjing Xu et al. Molecular Medicine Reports
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
- (2017) W. Joost Lesterhuis et al. NATURE REVIEWS DRUG DISCOVERY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance
- (2017) Bhargavi Pulluri et al. PHARMACOLOGICAL RESEARCH
- Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
- (2017) Meredith L. Stone et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
- (2017) Claire Lhuillier et al. SEMINARS IN CANCER BIOLOGY
- Predictors of responses to immune checkpoint blockade in advanced melanoma
- (2017) N. Jacquelot et al. Nature Communications
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells
- (2017) Nils-Petter Rudqvist et al. Cancer Immunology Research
- PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab
- (2017) Gabriele Madonna et al. OncoImmunology
- Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors
- (2017) Nathan O. Siemers et al. PLoS One
- Coinhibitory Pathways in Immunotherapy for Cancer
- (2016) Susanne H. Baumeister et al. Annual Review of Immunology
- In SituTumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments
- (2016) Zachary S. Morris et al. CANCER RESEARCH
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
- (2016) Laura Q.M. Chow et al. CLINICAL CANCER RESEARCH
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
- (2016) Toni K. Choueiri et al. CLINICAL CANCER RESEARCH
- Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
- (2016) KM Morrissey et al. CTS-Clinical and Translational Science
- Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
- (2016) Tai Hato et al. Immunotherapy
- Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells
- (2016) Koji Nakamura et al. MOLECULAR CANCER RESEARCH
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment
- (2016) MINGYUE LI et al. ONCOLOGY REPORTS
- Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells
- (2016) Shu Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer
- (2016) Hong Zheng et al. Oncotarget
- Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy
- (2016) A. M. Trotta et al. Cancer Immunology Research
- Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy
- (2016) D. B. Page et al. Cancer Immunology Research
- Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials
- (2016) Seongseok Yun et al. Cancer Medicine
- Current clinical trials testing the combination of immunotherapy with radiotherapy
- (2016) Josephine Kang et al. Journal for ImmunoTherapy of Cancer
- Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response inKRASwild-type metastatic colorectal cancer patients
- (2016) Cristiana Lo Nigro World Journal of Gastrointestinal Oncology
- Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine
- (2015) Yasuhiko Ohshio et al. CANCER SCIENCE
- Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
- (2015) Santiago Zelenay et al. CELL
- Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
- (2015) A. Filatenkov et al. CLINICAL CANCER RESEARCH
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
- (2015) Rebecca S. Heist et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy
- (2015) Jennifer A. Wargo et al. SEMINARS IN ONCOLOGY
- In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
- (2015) Claire Vanpouille-Box et al. VACCINE
- Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
- (2015) Andreas D. Ørskov et al. Oncotarget
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges
- (2014) Siwen Hu-Lieskovan et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiation-Induced IFN- Production within the Tumor Microenvironment Influences Antitumor Immunity
- (2014) A. A. Lugade et al. JOURNAL OF IMMUNOLOGY
- Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression
- (2014) liufu deng et al. OncoImmunology
- Targeting COX-2 abrogates mammary tumorigenesis
- (2014) Nune Markosyan et al. OncoImmunology
- Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy
- (2014) Jing Lu et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
- (2013) Vikash P. Chauhan et al. Nature Communications
- An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer
- (2013) E. B. Golden et al. Cancer Immunology Research
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Primary Tumor Hypoxia Recruits CD11b+/Ly6Cmed/Ly6G+Immune Suppressor Cells and Compromises NK Cell Cytotoxicity in the Premetastatic Niche
- (2012) Jaclyn Sceneay et al. CANCER RESEARCH
- Exosome removal as a therapeutic adjuvant in cancer
- (2012) Annette M Marleau et al. Journal of Translational Medicine
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma
- (2011) J. H. W. Pahl et al. CLINICAL CANCER RESEARCH
- VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Macrophage Expression of Hypoxia-Inducible Factor-1 Suppresses T-Cell Function and Promotes Tumor Progression
- (2010) A. L. Doedens et al. CANCER RESEARCH
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors
- (2010) Barbara Seliger et al. TRENDS IN MOLECULAR MEDICINE
- Systemic effects of local radiotherapy
- (2009) Silvia C Formenti et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation